Alvotech Investors with Losses Encouraged to Contact Hagens Berman.

Hagens Berman is investigating Alvotech, an Icelandic biopharmaceutical company, for potential securities law violations related to its disclosures about its lead drug candidate and manufacturing operations. The firm is scrutinizing the company's full-year financial forecasts and the propriety of its Biologics License Application for AVT05. Investors who suffered significant losses are encouraged to submit their losses now.